SB4 (Benepali ® ; an etanercept biosimilar): a profile of its use

AbstractSB4 [Benepali® (EU); Brenzys ™ (Australia, Canada, Korea)] is an etanercept biosimilar approved for all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis. In a pha se 3 trial in patients with moderate to severe rheumatoid arthritis receiving methotrexate, the efficacy of subcutaneous SB4 was equivalent to that of reference etanercept, and both agents had a similar tolerability profile, except for a higher incidence of injection-site reactions with reference et anercept. In patients switched from reference etanercept to SB4, there was no loss of efficacy or an increase in adverse events or immunogenicity. Switching to treatment with SB4, using a well-designed communication strategy, may potentially result in cost savings for healthcare budgets, thereby imp roving patient access to treatment.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research